September #105 : Trouble for Tipranavir - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Kissing Babies

The Demons Behind the Down Low

Hello Our Name Is ATAC

Putting Out

The DL 411: Resources

Bedtime for Bonzo

Using My Religion

Triple Threat



Pos & Neg

Planet Bollywood

Doing the HIV Cannes-Cannes

POZ's Bookmobile

How a Drug Becomes a Pill


Herbs & Hard-Ons

O Sole Mio!

Quick Study: Diarrhea

The Ideal Combo?

Write On!

Trouble for Tipranavir

HIV Spoken Here

Mouth Wide Shut

Married... with Virus


Lady in Waiting

Publisher's Letter

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

September 2004

Trouble for Tipranavir

by Tim Murphy

The next big drug hatches hitches

For nearly five years now, HIVers and activists have eagerly awaited tipranavir (TPV), the Boehringer-Ingelheim (BI) protease inhibitor (PI). With its reputedly high barrier against protease mutations, TPV had held promise for multidrug-resistant (MDR) HIVers and is expected to get FDA approval by mid-2005. But March brought grim tidings for anyone hoping TPV would soup up a pooped-out regimen. When researchers added it to various PI combos in HIVers with heavy PI resistance, TPV undermined the other PIs’ blood levels, perhaps explaining why the strategy vanquished viral load for only about a month. Houston MDR HIVer and treatment activist Nelson Vergel calls the finding “not very promising”—at least in terms of punching up old PIs.

But can TPV triumph if paired with another brand-new drug, such as Fuzeon (T-20)? That’s how some folks took it in the BI study, but inquiring minds won’t know until late fall when the company releases that data. BI virologist Scott McCallister, MD, dares to call those data “encouraging,” adding, “you should continue to be optimistic that [TPV] will find a useful place for treatment-experienced patients.” Let’s hope. Yet it likely needs boosting with twice the amount of ritonavir (Norvir) found in a daily dose of Kaletra (lopinavir plus ritonavir)—which would make for a daily Norvir tab of nearly $35 now that its maker, Abbott, has notoriously raised its price by 400 percent. So will anyone but the most desperate be able to take tipranavir?

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.